PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single Dose
- First Posted Date
- 2025-03-10
- Last Posted Date
- 2025-07-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 550
- Registration Number
- NCT06866405
- Locations
- 🇺🇸
Lucile Packard Children's Hospital-Labor and Delivery Unit, Palo Alto, California, United States
🇺🇸Lucile Packard Children's Hospital, Palo Alto, California, United States
🇺🇸Stanford University Medical Center, Palo Alto, California, United States
A Study to Learn About the Study Medicine - Zavicefta in Patients With Sepsis or Loss of Kidney Function in Japan
- Conditions
- Infectious Diseases
- Interventions
- Drug: Avibactam sodium/Ceftazidime hydrate
- First Posted Date
- 2025-03-07
- Last Posted Date
- 2025-06-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 59
- Registration Number
- NCT06864585
A Study to Learn if Study Medicines Called Cyclosporine and Clarithromycin Affect How the Body Processes the Other Study Medicine Called PF-07328948 in Healthy Adults
- Conditions
- Healthy Adults
- Interventions
- First Posted Date
- 2025-02-20
- Last Posted Date
- 2025-06-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 26
- Registration Number
- NCT06837259
- Locations
- 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium
A Study to Learn How Different Amounts of the Study Medicine Called PF-07314470 Are Tolerated and Act in the Body in Healthy Adults
- Conditions
- Healthy
- Interventions
- Biological: Placebo for PF-07314470
- First Posted Date
- 2025-02-12
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 103
- Registration Number
- NCT06821750
- Locations
- 🇺🇸
Pfizer Clinical Research Unit - New Haven, New Haven, Connecticut, United States
Effectiveness of ABRYSVO® Maternal Respiratory Syncytial Virus (RSV) Vaccine Against RSV in Infants in Western Pennsylvania
- Conditions
- Respiratory Syncytial Viruses
- Interventions
- Biological: ABRYSVO Vaccination
- First Posted Date
- 2025-02-07
- Last Posted Date
- 2025-07-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1
- Registration Number
- NCT06813872
- Locations
- 🇺🇸
Pfizer, New York, New York, United States
A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema
- First Posted Date
- 2025-02-04
- Last Posted Date
- 2025-06-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 150
- Registration Number
- NCT06807268
- Locations
- 🇺🇸
Arkansas Research Trials, North Little Rock, Arkansas, United States
🇺🇸Dawes Fretzin Clinical Research Group, LLC, Indianapolis, Indiana, United States
🇺🇸Centricity Research Dublin Multispecialty, Dublin, Ohio, United States
A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
- First Posted Date
- 2025-02-04
- Last Posted Date
- 2025-06-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 500
- Registration Number
- NCT06807281
A Study to Learn About the Study Medicine Called PF-08046031 in Advanced Melanoma and Other Solid Tumors
- Conditions
- Malignant MelanomaMelanomaMetastatic MelanomaSolid Tumors
- Interventions
- First Posted Date
- 2025-01-29
- Last Posted Date
- 2025-06-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 185
- Registration Number
- NCT06799533
- Locations
- 🇺🇸
The Angeles Clinic and Research Institue, A Cedars-Sinai Affiliate, Los Angeles, California, United States
🇺🇸The Angeles Clinic and Research Institue, A Cedars-Sinai Affiliate (Emergency Back-up only), Santa Monica, California, United States
🇺🇸Sarah Cannon Research Institute at HealthONE - SCRI - PPDS, Denver, Colorado, United States
RITUXIMAB BS Intravenous Infusion 100mg・500mg [Pfizer] Post-marketing Database Study
- First Posted Date
- 2025-01-24
- Last Posted Date
- 2025-05-31
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1
- Registration Number
- NCT06790420
- Locations
- 🇯🇵
Pfizer, Tokyo, Japan
A Study to Learn About How Well the Prevnar 20 Vaccine Works for Pneumonia in People Who Are 65 Years and Older
- Conditions
- Community-Acquired Pneumonia (CAP)
- First Posted Date
- 2025-01-17
- Last Posted Date
- 2025-06-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 22234435
- Registration Number
- NCT06782282
- Locations
- 🇺🇸
Pfizer United States, New York, New York, United States